Analysts forecast that Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) will report $2.17 billion in sales for the current quarter, Zacks reports. Five analysts have provided estimates for Valeant Pharmaceuticals International’s earnings. The highest sales estimate is $2.25 billion and the lowest is $2.12 billion. Valeant Pharmaceuticals International posted sales of $2.48 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 12.5%. The business is expected to report its next quarterly earnings report on Tuesday, November 14th.

According to Zacks, analysts expect that Valeant Pharmaceuticals International will report full year sales of $2.17 billion for the current financial year, with estimates ranging from $8.51 billion to $8.88 billion. For the next year, analysts anticipate that the firm will post sales of $8.65 billion per share, with estimates ranging from $7.97 billion to $9.96 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Valeant Pharmaceuticals International.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. The firm had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. Valeant Pharmaceuticals International’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.88) earnings per share.

Several equities research analysts recently issued reports on the stock. BMO Capital Markets reissued a “hold” rating and issued a $15.00 target price on shares of Valeant Pharmaceuticals International in a research report on Thursday, July 27th. Zacks Investment Research raised shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 27th. Deutsche Bank AG set a $19.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Monday, July 17th. J P Morgan Chase & Co set a $10.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Monday, July 17th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $35.00 target price on shares of Valeant Pharmaceuticals International in a research report on Friday, June 30th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $17.67.

In related news, Director Schutter Richard U. De acquired 10,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were purchased at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the acquisition, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 5.87% of the company’s stock.

A number of large investors have recently made changes to their positions in VRX. Capstone Asset Management Co. boosted its position in shares of Valeant Pharmaceuticals International by 13.6% in the 1st quarter. Capstone Asset Management Co. now owns 32,988 shares of the specialty pharmaceutical company’s stock worth $364,000 after purchasing an additional 3,940 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Valeant Pharmaceuticals International by 3.8% in the 1st quarter. Nationwide Fund Advisors now owns 51,500 shares of the specialty pharmaceutical company’s stock worth $568,000 after purchasing an additional 1,900 shares in the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Valeant Pharmaceuticals International by 4.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 19,573 shares of the specialty pharmaceutical company’s stock worth $216,000 after purchasing an additional 848 shares in the last quarter. Great West Life Assurance Co. Can increased its stake in shares of Valeant Pharmaceuticals International by 3.1% in the 1st quarter. Great West Life Assurance Co. Can now owns 248,876 shares of the specialty pharmaceutical company’s stock worth $2,736,000 after purchasing an additional 7,511 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Valeant Pharmaceuticals International by 4.1% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 476,585 shares of the specialty pharmaceutical company’s stock worth $5,263,000 after purchasing an additional 18,727 shares in the last quarter. Institutional investors own 50.49% of the company’s stock.

WARNING: “$2.17 Billion in Sales Expected for Valeant Pharmaceuticals International, Inc. (VRX) This Quarter” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/09/2-17-billion-in-sales-expected-for-valeant-pharmaceuticals-international-inc-vrx-this-quarter.html.

Valeant Pharmaceuticals International (NYSE:VRX) opened at 13.61 on Friday. The firm has a 50-day moving average of $14.87 and a 200 day moving average of $13.27. The firm’s market capitalization is $4.74 billion. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $28.93.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get a free copy of the Zacks research report on Valeant Pharmaceuticals International (VRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.